Another Drug Price Hike

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, AYENAOut-of-control pharmaceutical price-hiking is in the news again. After a Congressional investigation into the practice of drugmaker Valeant Pharmaceuticals buying older heart medications and raising their prices exponentially, the firm is on the hot seat once again—this time for doubling the price of a decades-old sleeping pill that is now used in instances of assisted suicide. Doctors prescribe the pill, Seconal (secobarbital), in cases of physician-assisted suicide, which voters in California made legal starting this June. Valeant bought the rights to Seconal last February—a month after California legislators proposed legalizing physician-assisted suicide—and immediately raised its price from $1,500 to $,3000.

“It’s just pharmaceutical company greed,” David Grube, a family physician in Oregon, told KQED, the San Francisco-based public radio station that broke the story. “It’s not a complicated thing to make, there’s no research being done on it, there’s no development,” he added. “That to me is unconscionable.”

Valeant came under fire last year when the company inflated the prices of two heart medications by 200 percent and 500 percent. The House of Representatives is still investigating those cases of alleged price gouging, The New York Times reported.

“Valeant sets prices for drugs based on a number of factors,” the company told KQED in a statement. “When possible, we offer patient assistance programs to mitigate the effects of price adjustments and keep out-of-pocket costs affordable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo
An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

sartorius logo
Unlocking the Unattainable in Gene Construction

Unlocking the Unattainable in Gene Construction

dna-script-primarylogo-digital
Concept illustration of acoustic waves and ripples.

Comparing Analytical Solutions for High-Throughput Drug Discovery

sciex

Products

Green Cooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Thermo Fisher Logo
Singleron Avatar

Singleron Biotechnologies and Hamilton Bonaduz AG Announce the Launch of Tensor to Advance Single Cell Sequencing Automation

Zymo Research Logo

Zymo Research Launches Research Grant to Empower Mapping the RNome

Magid Haddouchi, PhD, CCO

Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer